MCID: PRP007
MIFTS: 51

Priapism

Categories: Cardiovascular diseases, Genetic diseases, Rare diseases, Reproductive diseases

Aliases & Classifications for Priapism

MalaCards integrated aliases for Priapism:

Name: Priapism 12 53 55 44 15 73
Priapism, Familial Idiopathic 53 73
Familial Idiopathic Priapism 53
Mentulagra 12

Classifications:



External Ids:

Disease Ontology 12 DOID:9286
ICD10 33 N48.3 N48.30
ICD9CM 35 607.3
MeSH 44 D011317
NCIt 50 C85022
SNOMED-CT 68 4287008 6273006

Summaries for Priapism

Disease Ontology : 12 A peripheral vascular disease characterized by blood trapped in the penis that is unable to drain.

MalaCards based summary : Priapism, also known as priapism, familial idiopathic, is related to impotence and sexual disorder, and has symptoms including painful erection An important gene associated with Priapism is PDE5A (Phosphodiesterase 5A), and among its related pathways/superpathways are Response to elevated platelet cytosolic Ca2+ and Apoptosis Pathway. The drugs Prazosin and Acetylcysteine have been mentioned in the context of this disorder. Affiliated tissues include myeloid, prostate and kidney, and related phenotypes are cardiovascular system and homeostasis/metabolism

Wikipedia : 76 Priapism is a condition in which a penis remains erect for hours in the absence of stimulation or after... more...

Related Diseases for Priapism

Diseases related to Priapism via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 140)
# Related Disease Score Top Affiliating Genes
1 impotence 30.7 NOS3 PDE5A
2 sexual disorder 29.9 NOS3 PDE5A
3 vasculogenic impotence 29.8 NOS3 PDE5A
4 thrombophilia due to thrombin defect 29.8 F13A1 F5
5 homocysteinemia 29.5 F5 NOS3
6 intracranial hypertension 29.5 AQP1 F5
7 autosomal dominant polycystic kidney disease 29.4 AQP1 KL NOS3
8 myocardial infarction 29.3 F13A1 F5 NOS3 PDE5A
9 low-flow priapism 12.4
10 priapism, familial idiopathic 12.0
11 persistent genital arousal disorder 11.4
12 sickle cell disease 10.6
13 stuttering 10.5
14 sickle cell anemia 10.4
15 leukemia 10.3
16 myeloid leukemia 10.2
17 penile disease 10.1 NOS3 PDE5A
18 thrombosis 10.1
19 adenocarcinoma 10.1
20 persistent fetal circulation syndrome 10.1 NOS3 PDE5A
21 carotid artery occlusion 10.1 F5 NOS3
22 factor xiii deficiency 10.1 F13A1 F5
23 prostate cancer 10.1
24 schizophrenia 10.1
25 thalassemia 10.1
26 acquired angioedema 10.1 F5 HP
27 intracranial vasospasm 10.1 HP NOS3
28 dysfibrinogenemia 10.1 F13A1 F5
29 spinal cord injury 10.1
30 arteritic anterior ischemic optic neuropathy 10.0 F5 NOS3 PDE5A
31 ischemic optic neuropathy 10.0 F5 NOS3 PDE5A
32 nonarteritic anterior ischemic optic neuropathy 10.0 F5 NOS3 PDE5A
33 purpura 10.0
34 coronary artery anomaly 9.9 F5 HP NOS3
35 prostatic hyperplasia, benign 9.9 ADRA1A PDE5A
36 myeloma, multiple 9.9
37 fabry disease 9.9
38 suppression of tumorigenicity 12 9.9
39 spinal stenosis 9.9
40 hemoglobinopathy 9.9
41 protein c deficiency 9.9
42 appendicitis 9.9
43 bladder cancer 9.9
44 renal cell carcinoma, nonpapillary 9.9
45 systemic lupus erythematosus 9.9
46 autism 9.9
47 anxiety 9.9
48 malaria 9.9
49 beta-thalassemia 9.9
50 arteriovenous fistula 9.9

Graphical network of the top 20 diseases related to Priapism:



Diseases related to Priapism

Symptoms & Phenotypes for Priapism

UMLS symptoms related to Priapism:


painful erection

MGI Mouse Phenotypes related to Priapism:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.06 ADRA1A AQP1 F13A1 F5 HP ITGAV
2 homeostasis/metabolism MP:0005376 9.92 ADRA1A AQP1 F13A1 F5 HP ITGAV
3 hematopoietic system MP:0005397 9.91 AQP1 F13A1 HP ITGAV KL NOS3
4 mortality/aging MP:0010768 9.81 ADRA1A AQP1 F13A1 F5 HP ITGAV
5 liver/biliary system MP:0005370 9.65 F5 HP KL NOS3 TGFBR3
6 muscle MP:0005369 9.35 ADRA1A ITGAV KL NOS3 TGFBR3
7 renal/urinary system MP:0005367 9.1 ADRA1A AQP1 HP ITGAV KL NOS3

Drugs & Therapeutics for Priapism

Drugs for Priapism (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 50)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Prazosin Approved Phase 3 19216-56-9 4893
2
Acetylcysteine Approved, Investigational Phase 3 616-91-1 12035
3 Antihypertensive Agents Phase 3
4 Adrenergic alpha-1 Receptor Antagonists Phase 3
5 Adrenergic alpha-Antagonists Phase 3
6 Neurotransmitter Agents Phase 3
7 Adrenergic Agents Phase 3
8 Adrenergic Antagonists Phase 3
9 Antidotes Phase 3
10 Anti-Infective Agents Phase 3,Phase 2,Phase 1
11 Expectorants Phase 3
12 N-monoacetylcystine Phase 3
13 Protective Agents Phase 3
14 Antioxidants Phase 3
15 Free Radical Scavengers Phase 3
16 Antiviral Agents Phase 3
17 Respiratory System Agents Phase 3
18
Hydroxyurea Approved Phase 2,Phase 1 127-07-1 3657
19
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
20
Chlorhexidine Approved, Vet_approved Phase 2 55-56-1 2713 9552079
21
Sirolimus Approved, Investigational Phase 1, Phase 2,Phase 2 53123-88-9 46835353 6436030 5284616
22
Everolimus Approved Phase 1, Phase 2,Phase 2 159351-69-6 6442177
23
Miconazole Approved, Investigational, Vet_approved Phase 1, Phase 2,Phase 2 22916-47-8 4189
24
alemtuzumab Approved, Investigational Phase 1, Phase 2,Phase 2 216503-57-0
25
Cyclophosphamide Approved, Investigational Phase 2 6055-19-2, 50-18-0 2907
26
Citric Acid Approved, Nutraceutical, Vet_approved Phase 2 77-92-9 311
27 Citrate Phase 2
28 Phosphodiesterase Inhibitors Phase 2
29 Sildenafil Citrate Phase 2 171599-83-0
30 Phosphodiesterase 5 Inhibitors Phase 2
31 Vasodilator Agents Phase 2
32 Antibodies, Monoclonal Phase 2
33 Antibodies Phase 2
34 Nucleic Acid Synthesis Inhibitors Phase 2
35 Immunoglobulins Phase 2
36 Anti-Infective Agents, Local Phase 2
37 Dermatologic Agents Phase 2
38 Chlorhexidine gluconate Phase 2
39 Analgesics Phase 2
40 Disinfectants Phase 2
41 Anti-Bacterial Agents Phase 1, Phase 2,Phase 2
42 Antibiotics, Antitubercular Phase 1, Phase 2,Phase 2
43 Immunosuppressive Agents Phase 1, Phase 2,Phase 2
44 Antifungal Agents Phase 1, Phase 2,Phase 2
45 Immunologic Factors Phase 1, Phase 2,Phase 2
46 Pharmaceutical Solutions Phase 2
47 Antirheumatic Agents Phase 2
48 Antineoplastic Agents, Alkylating Phase 2
49 Trichostatin A Phase 2
50 Alkylating Agents Phase 2

Interventional clinical trials:

(show all 19)
# Name Status NCT ID Phase Drugs
1 AScVS and/ or Prazosin for Scorpion Envenomation Completed NCT00753064 Phase 3 Antiscorpion venom serum(AScVS).;T.Prazosin;AScVS + Prazosin
2 N-Acetylcysteine in Patients With Sickle Cell Disease Completed NCT01849016 Phase 3 N-Acetylcysteine;Placebo
3 Differential Effect of Silodosin Versus Tamsulosin on Stone Clearance After Extra-corporeal Shock Wave Lithotripsy Withdrawn NCT01560091 Phase 3 silodosin;Tamsulosin
4 Sildenafil for Treatment of Priapism in Men With Sickle Cell Anemia Completed NCT00940901 Phase 2 sildenafil
5 Intracavernous Bone Marrow Stem-cell Injection for Post Prostatectomy Erectile Dysfunction Completed NCT01089387 Phase 1, Phase 2
6 Study to Assess Safety and Impact of SelG1 With or Without Hydroxyurea Therapy in Sickle Cell Disease Patients With Pain Crises Completed NCT01895361 Phase 2 SelG1;Placebo
7 Urethral Sterilization With Chlorhexidine Digluconate to Facilitate Primary Repair & Same-Session Implantation Recruiting NCT03614429 Phase 2 Chlorhexidine gel will be prepared according to an international product Instillagel®
8 Ph I/II Study of Allogeneic SCT for Clinically Aggressive Sickle Cell Disease (SCD) Recruiting NCT01499888 Phase 1, Phase 2 Alemtuzumab;Sirolimus
9 Pharmacokinetics and Pharmacodynamics Study of SEG101 (Crizanlizumab) in Sickle Cell Disease (SCD) Patients With Vaso- Occlusive Crisis (VOC) Recruiting NCT03264989 Phase 2 crizanlizumab
10 Study of Dose Confirmation and Safety of Crizanlizumab in Pediatric Sickle Cell Disease Patients Recruiting NCT03474965 Phase 2 Crizanlizumab
11 SCD-Haplo: Phase II Study of HLA-Haploidentical SCT for Aggressive SCD Active, not recruiting NCT02013375 Phase 2 Alemtuzumab;Cyclophosphamide;Sirolimus
12 Evaluation of Different Dose Regimens of Aes-103 Given for 28 Days to Subjects With Stable Sickle Cell Disease Terminated NCT01987908 Phase 2 Aes-103
13 Tadalafil for Treatment of Priapism in Men With Sickle Cell Anemia Withdrawn NCT00538564 Phase 2 tadalafil;placebo
14 Sildenafil for Prevention of Cerebral Vasospasm Withdrawn NCT01091870 Phase 2 Placebo;Sildenafil Citrate, 25 mg, 3 times a day.;Sildenafil Citrate 50 mg, 3 times a day
15 Priapism in Boys and Men With Sickle Cell Disease - Demographics, Characteristics and Prevalence Completed NCT00300235
16 Sleep Study in Adult Patients With Major Sickle Cell Disease With Paroxysmal Nocturnal Events Recruiting NCT02539771 Not Applicable
17 Substudy of CADRE: for People With Extreme Phenotype: BIOCADRE Recruiting NCT03352986
18 Heart Arteries and Sickle Cell Disease / Coeur Artères DREpanocytose Recruiting NCT03114137
19 Androgen Regulation of Priapism in Sickle Cell Disease Withdrawn NCT01940718 Early Phase 1 Transdermal Androgel

Search NIH Clinical Center for Priapism

Cochrane evidence based reviews: priapism

Genetic Tests for Priapism

Anatomical Context for Priapism

MalaCards organs/tissues related to Priapism:

41
Myeloid, Prostate, Kidney, Spinal Cord, Brain, Lung, Tongue

Publications for Priapism

Articles related to Priapism:

(show top 50) (show all 1064)
# Title Authors Year
1
Superselective Transcatheter Artery Embolization in Patients with Non-ischemic Priapism. ( 29417263 )
2018
2
Molecular Profile of Priapism Associated with Low Nitric Oxide Bioavailability. ( 29394072 )
2018
3
Priapism caused by "Rhino 7 Platinum 3000" an over-the-counter male enhancement supplement. ( 29915255 )
2018
4
Daily tadalafil for the chronic phase of stuttering priapism: a case report. ( 29855284 )
2018
5
Priapism in sickle cell disease: Beware of neuroleptics. ( 29885077 )
2018
6
Comment on "Olanzapine-induced Priapism in a Child with Asperger's Syndrome". ( 29666039 )
2018
7
Prevalence and Characteristics of Priapism in Sickle Cell Disease. ( 29745276 )
2018
8
Through Clinical Observation: The History of Priapism After Spinal Cord Injuries. ( 29054772 )
2018
9
BAUS Consensus Document for the Management of Male Genital Emergencies - Priapism. ( 29357203 )
2018
10
Penoscrotal Decompression-Promising New Treatment Paradigm for Refractory Ischemic Priapism. ( 29550463 )
2018
11
Priapism as the initial sign in hematologic disease: Case report and literature review. ( 29414500 )
2018
12
Successful Management of Psychotropics Induced Stuttering Priapism with Pseudoephedrine in a Patient with Schizophrenia. ( 29713098 )
2018
13
Clitoral priapism due to distant clitoral metastasis of high-grade serous ovarian carcinoma: A case report and review of the literature. ( 29915806 )
2018
14
Case - Temporary chemical castration in the management of recurrent priapism. ( 29405906 )
2018
15
High-flow priapism and urinary retention. ( 29888190 )
2018
16
Priapism and hemodialysis: Case report and literature reviewa8c. ( 29578404 )
2018
17
Recent advances in the management of priapism. ( 29375820 )
2018
18
Prognosis of men with penile metastasis and malignant priapism: a systematic review. ( 29416825 )
2018
19
History of posttraumatic stress disorder A^ priapism A^ Dx? ( 29879245 )
2018
20
Spontaneous detumescence and full restoration of erection in a patient with high-flow priapism with persistent arterial-lacunar fistula after repeated selective embolisation-A case report. ( 29687468 )
2018
21
Poorly Controlled Homocystinuria: A Rare Cause of Ischemic Priapism? ( 29463473 )
2018
22
Commentary to "Ischemic priapism in pediatric patients: spontaneous detumescence with ketamine sedation". ( 29807704 )
2018
23
Ischemic priapism in pediatric patients: Spontaneous detumescence with ketamine sedation. ( 29936034 )
2018
24
Malignant priapism in metastatic prostate cancer: A late event occurring early. ( 29888172 )
2018
25
Penile Metastasis from Prostate Cancer Presenting as Malignant Priapism Detected Using Gallium-68 Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography. ( 29430118 )
2018
26
Posttraumatic High-Flow Nonischemic Priapism. ( 29601467 )
2018
27
Role of Penile Prosthesis in Priapism: A Review. ( 29299902 )
2018
28
A new cause of ischaemic priapism: Synthetic cannabinoids. ( 29607523 )
2018
29
The first case of neonatal priapism during hypothermia for hypoxic-ischemic encephalopathy and a literature review. ( 30053817 )
2018
30
Urologic Management of Priapism Secondary to Chronic Myeloid Leukemia. ( 30471371 )
2018
31
Priapism as a rare presentation of chronic myeloid leukemia. ( 30488874 )
2018
32
Combination High Flow Priapism With Low Flow Priapism: Case Report. ( 30522977 )
2018
33
Nonischemic Priapism in Childhood: A Case Series and Review of Literature. ( 28346955 )
2018
34
Emergency Management of Priapism in the United Kingdom: A Survey of Current Practice. ( 29454716 )
2018
35
The role of apoptosis and the effect of epidermal growth factor on proapoptotic BNIP 3 in an experimental rat priapism model ( 29479984 )
2018
36
Management of priapism with a trial of exercise in the emergency department. ( 29547365 )
2018
37
The Risks of Using Herbal Supplements for Sexual Dysfunction Associated With Psychotropic Medications: A Case Report of ExtenZe Use and Priapism. ( 29553994 )
2018
38
Priapism Throughout the Ages. ( 29729364 )
2018
39
The Hemodynamic Effects of Intracavernosal Phenylephrine for the Treatment of Ischemic Priapism. ( 29960632 )
2018
40
Selective Penile Arterial Embolization Preserves Long-Term Erectile Function in Patients with Nonischemic Priapism: An 18-Year Experience. ( 30059714 )
2018
41
Efficacy and Safety of Treatment of High-flow Priapism with Superselective Transcatheter Embolization. ( 30074158 )
2018
42
A Rare Case of Severe Idiopathic Stuttering Priapism in a Young Healthy Man. ( 30094115 )
2018
43
Penile fracture after priapism due to sildenafil ingestion: out of frying pan into the fire. ( 30108124 )
2018
44
Priapism induced by various Psychotropics: A Case Series. ( 30208753 )
2018
45
Self-care of men with priapism and sickle cell disease. ( 30304171 )
2018
46
Chronic myeloid leukaemia presenting as priapism: A case report from Khyber Pakhtunkhwa. ( 30323364 )
2018
47
Selective arterial embolization for a high-flow priapism following perineal trauma in a young gymnast. ( 30362692 )
2018
48
Re: Emergency Management of Priapism in the United Kingdom: A Survey of Current Practice. ( 30412968 )
2018
49
Unintended Consequences: A Review of Pharmacologically-Induced Priapism. ( 30503727 )
2018
50
Case 3: Priapism in a 13-year-old Boy. ( 30504255 )
2018

Variations for Priapism

Expression for Priapism

Search GEO for disease gene expression data for Priapism.

Pathways for Priapism

GO Terms for Priapism

Cellular components related to Priapism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 integral component of plasma membrane GO:0005887 9.02 ADRA1A AQP1 ITGAV KL TGFBR3
2 platelet alpha granule lumen GO:0031093 8.96 F13A1 F5

Biological processes related to Priapism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 response to hormone GO:0009725 9.26 ADRA1A NOS3
2 hemostasis GO:0007599 9.16 F13A1 F5
3 ventricular septum morphogenesis GO:0060412 8.96 NOS3 TGFBR3
4 positive regulation of cardiac muscle hypertrophy GO:0010613 8.62 ADRA1A PDE5A

Molecular functions related to Priapism according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 coreceptor activity GO:0015026 9.16 ITGAV TGFBR3
2 transforming growth factor beta binding GO:0050431 8.96 ITGAV TGFBR3
3 fibroblast growth factor binding GO:0017134 8.8 ITGAV KL TGFBR3

Sources for Priapism

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
Content
Loading form....